The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Proxofim
FOXO4-DRI is the compound that makes the strongest biological argument for a transformative longevity intervention in this book — and the compound that makes the strongest argument for waiting for human safety data before self-experimenting. These are not contradictory positions. They reflect the actual state of evidence.
The central tension resolved: the 2017 Baar et al. Cell paper is genuinely extraordinary. A compound that selectively eliminates senescent cells by releasing p53 from sequestration, restoring fur, renal function, and physical fitness in aged mice, and extending median lifespan by 24.8% — this is not marginal biology. If the mechanism translates to humans at accessible doses, FOXO4-DRI or its analogs could represent one of the most significant longevity therapeutic advances in history. The compound works by interacting with p53 — the tumor suppressor that, when disrupted or mutated, enables most human cancers. Seven years after the landmark paper, no human safety trial has been initiated. Every longevity-focused biohacker who is injecting FOXO4-DRI is doing so without any human safety data for the class of compound they are using. That is a very different risk profile from other experimental compounds, where the risk is primarily 'we don't know if it works.' Here, the risk is 'we don't know if it's safe, and the mechanism is the same one that matters most for cancer prevention.'
The strongest argument for FOXO4-DRI: the selectivity mechanism is elegant and independently replicated in multiple cell types by multiple groups. The original paper is from a premier aging research institution, not a commercial developer. The independent replications (chondrocytes, endothelial cells, keloid fibroblasts) confirm the basic senolytic mechanism works in human cells — not just mouse tissue. Cleara Biotech's clinical development program (Proxofim) targeting kidney disease and COPD is a positive signal that someone with regulatory accountability has assessed this compound as worthy of clinical development. Senescent cell clearance is one of the most mechanistically compelling anti-aging strategies in academic geroscience.
The strongest argument for caution: p53. Every argument for caution flows from the p53 mechanism. The compound modulates p53 availability in cells. p53 dysfunction is found in ~50% of all human cancers. The community using this compound self-administers it without any characterization of their p53 pathway status, without any tumor burden assessment, and without any physician oversight of the theoretical cancer risk. The absence of reported adverse events in community use is consistent with the compound being safe — but community self-reporting is not a safety monitoring system. Undetected adverse events (a slowly progressing cancer in a p53-compromised context, for example) would not show up in community forums for years.
In 2017, a team at Erasmus University Medical Center in Rotterdam published a paper in Cell that described what might be the most remarkable rejuvenation experiment in the history of longevity research. Old mice, injected with a synthetic peptide for three weeks, recovered physical fitness. Their kidneys started functioning like younger animals. And then the detail that made the paper go viral in every longevity community on the internet: their fur grew back.
The lead researcher was Marjolein Baar, working in the laboratory of Jan Hoeijmakers at Erasmus, one of Europe's premier DNA damage and aging research centers. The compound they had synthesized was FOXO4-DRI: a D-retro-inverso version of a peptide designed to disrupt the interaction between two proteins — FOXO4 and p53 — that were specifically relevant to the biology of cellular senescence.
To understand why this matters requires understanding cellular senescence. When cells sustain damage — DNA breaks, telomere erosion, oncogene activation — they face a choice: repair, die, or enter senescence. Senescence is a cellular state of permanent cell cycle arrest: the cell stops dividing but does not die. Instead, it lingers, metabolically active, secreting a cocktail of inflammatory cytokines, proteases, and growth factors collectively known as the senescence-associated secretory phenotype (SASP). This SASP is useful acutely — it recruits immune cells to clear damage and promotes wound healing. But when senescent cells accumulate in aging tissues over decades — when the immune system loses the capacity to clear them fast enough — the SASP drives chronic inflammation, impairs stem cell function, and degrades the tissue microenvironment in the organs where those cells reside.
The question Baar et al. asked was: what makes senescent cells resistant to death? Why don't they just die, given that they have sustained the kind of damage that would normally trigger apoptosis? The answer they found centered on two proteins. p53 — famously known as 'the guardian of the genome' — is the cell's primary apoptosis trigger. When damage is detected and irreparable, p53 activates the death program. But in senescent cells, they discovered that FOXO4 (a transcription factor specifically upregulated in senescent cells at 10-20x the level in healthy cells) binds to p53 in the nucleus and sequesters it — holding it in a conformation that prevents it from triggering apoptosis. The senescent cell uses FOXO4 to hold its own death switch in the off position.
FOXO4-DRI was designed as a competitor for that binding site. A peptide whose sequence mirrored the portion of FOXO4 that contacts p53, synthesized using D-amino acids in reverse order — the D-retro-inverso design — so that it would be structurally similar to the endogenous FOXO4 binding domain but resistant to the proteases that would rapidly destroy a conventional L-amino acid peptide. When FOXO4-DRI enters a cell, it outcompetes endogenous FOXO4 for p53 binding. P53, freed from sequestration, translocates out of the nucleus and to the mitochondria, activating the intrinsic apoptosis pathway. The cell dies.
The results in aged mice were striking by any standard. Three weeks of treatment (5 mg/kg intraperitoneally, every other day) produced: restored fur density in mice with the patchy fur characteristic of accelerated aging; improved renal function measured by creatinine clearance; improved physical fitness on treadmill endurance tests; and in a cohort followed for lifespan, a median survival extension of 24.8%. The effect was not achieved by slowing aging — it was achieved by removing the cells whose presence was driving age-related dysfunction. And crucially, senescent cell burden returned to pre-treatment levels within 8-12 weeks after treatment stopped, implying that the biology producing new senescent cells was unchanged; FOXO4-DRI merely cleared the existing burden.
THE CENTRAL TENSION — AND WHY IT CANNOT BE DISMISSED
FOXO4-DRI is the most biologically interesting compound in the longevity section of this book. The selectivity mechanism is elegant and well-characterized. The 2017 data is genuinely dramatic. The community has responded by immediately self-experimenting at scale. And here is the problem that must be stated clearly: p53 is 'the guardian of the genome' — the most important tumor suppressor in the human body. It is mutated or non-functional in approximately 50% of all human cancers. Compounds that modulate p53 function — in any direction — carry inherent and serious potential for off-target consequences that are not predictable without human safety data. FOXO4-DRI disrupts the FOXO4-p53 interaction specifically. But p53 interacts with dozens of proteins in many cellular contexts. The theoretical cancer risk from modulating p53 interactions in the wrong cellular context is not documented harm — the mice were fine, and the in vitro selectivity data is real. But it is also not zero. This risk needs to be held alongside the longevity promise throughout this chapter.
The evidence base is primarily the 2017 Cell paper and subsequent cell culture replications. Every systemic benefit described below is documented in animal models or in vitro. No system-by-system evidence in humans exists.
The most visually striking finding from the Baar 2017 [1] paper was restoration of physical fitness in naturally aged mice. Animals on the chemotherapy-accelerated aging model and naturally aged animals both showed improved performance on treadmill endurance and other physical function tests after three weeks of FOXO4-DRI treatment. In naturally aged mice, the restoration of fur density — lost as follicle stem cell niches become dominated by SASP-secreting senescent cells — was the visible marker of the systemic tissue microenvironment improvement. These physical function improvements were not marginal enhancements — they represented a return toward younger functional profiles after clearing accumulated senescent cell burden. Grade C: single primary study; dramatic and independently striking; needs independent full replication of the lifespan and functional data.
Kidney tubular cell senescence accumulates with age and contributes to age-related glomerular filtration decline. The Baar 2017 paper documented improved creatinine clearance and reduced p16INK4a-positive cell burden in renal tissue by approximately 30% after FOXO4-DRI treatment. Subsequent endothelial cell studies (2025-2026, Frontiers in Bioengineering) specifically confirmed that FOXO4-DRI reduces senescent endothelial cell burden in vascular tissue and improves endothelial function markers in aged and diabetic models. Cleara Biotech's clinical development program for Proxofim specifically targets kidney disease as the primary clinical indication — suggesting the renal senescence biology is the most translatable near-term application. Grade C: animal model and cell culture; Cleara's clinical focus adds translational signal.
The most recent independent replication work (Frontiers in Bioengineering, January 2026) focused specifically on endothelial cell senescence — a major driver of vascular aging. FOXO4-DRI reduced senescent endothelial cell burden, improved endothelial function markers, and delayed vascular aging in both naturally aged and progeroid mouse models. The mechanism confirmed: p53/BCL-2/Caspase-3 pathway activation in senescent endothelial cells after FOXO4-p53 disruption. This is independent replication from Chinese universities with no connection to the Erasmus group. Grade C: 2025-2026 independent publication; relevant to cardiovascular aging; animal model only.
A 2021 Frontiers in Bioengineering paper from a different independent group (cartilage tissue engineering) tested FOXO4-DRI in expanded human chondrocytes in vitro. Selective removal of senescent chondrocytes was confirmed — p16INK4a-positive cells declined, proliferating cells were unaffected. The authors proposed FOXO4-DRI as a potential tool to improve the quality of autologous chondrocyte implantation (ACI) therapy by clearing senescent cells from expanded cultures before reimplantation. This is the most directly relevant human cell data — expanded human chondrocytes, not mouse tissue. Grade C: human cell culture; in vitro; relevant to osteoarthritis and cartilage regeneration contexts. Cleara Biotech's indication list includes osteoarthritis.
The secondary finding in the Baar 2017 paper was particularly clinically relevant: FOXO4-DRI reversed chemotherapy-induced senescence in the doxorubicin-treated mouse model. Chemotherapy reliably induces senescence in normal tissues as a side effect of its DNA-damaging mechanism. The accumulated SASP from chemotherapy-induced senescence contributes to the 'chemobrain' cognitive effects, fatigue, and accelerated aging phenotypes that cancer survivors experience. FOXO4-DRI treatment after doxorubicin reversed body weight loss, reduced liver damage markers, and improved physical function in these models. Grade C: single study; one of the most clinically interesting findings given the large population of cancer survivors experiencing chemotherapy-accelerated aging.
The fur restoration in naturally aged mice in the original study implicates follicle stem cell niche rescue after senescent cell clearance. Senescent fibroblasts in the dermal niche inhibit hair follicle stem cell activation through their SASP. Clearing them restored niche conditions permissive to follicle cycling. Implications for human hair loss in aging: mechanistically coherent; not tested in a clinical hair loss study.
FOXO4-DRI is a D-retro-inverso (DRI) peptide. This designation describes a specific class of synthetic peptides designed to overcome a fundamental limitation of therapeutic peptides: proteolytic degradation. Standard peptides use L-amino acids (the naturally occurring stereoisomers) linked in sequence from N-terminus to C-terminus. The body's proteases — the enzymes that break down proteins and peptides — are exquisitely adapted to cleave L-amino acid sequences. Most injected therapeutic peptides have plasma half-lives of minutes to hours because proteases degrade them rapidly.
The D-retro-inverso design circumvents this in an elegant way. It uses D-amino acids (the mirror-image stereoisomers of natural amino acids) assembled in the reverse sequence order (retro = reversed, inverso = mirror image). This combination produces a peptide that is sterically similar to the original L-amino acid sequence from the perspective of receptor binding — the side chains point in the same directions when the backbone is oriented correctly — but is essentially invisible to proteases, which cannot cleave D-amino acid bonds. The result: dramatically extended biological half-life in tissues, potentially hours to days rather than minutes. This extended persistence is what makes FOXO4-DRI effective in vivo — it can penetrate cells and disrupt the FOXO4-p53 interaction before being cleared.
FOXO4-DRI molecular weight: approximately 4,826 Da (though sources vary from 4,796 to 4,963 Da, reflecting different exact sequence lengths and purity conventions). The peptide targets the p53-binding domain of FOXO4, specifically designed around the FOXO4 BH3-like domain that mediates its interaction with p53 in the nucleus. The 2025 Nature Communications structural study provided the first detailed crystallographic characterization of the FOXO4-p53 interaction site, confirming the binding geometry that FOXO4-DRI was designed to disrupt and enabling more precise analog development.
The D-retro-inverso design confers exceptional proteolytic stability. Unlike standard L-peptides (BPC-157, TB-500, GHK-Cu, ipamorelin), FOXO4-DRI does not require the same urgency around proteolytic degradation during storage and handling. However, standard lyophilized peptide storage protocols still apply: -20C for long-term storage; 2-8C after reconstitution; use within 30 days of reconstitution; avoid repeated freeze-thaw cycles. Unlike GHK-Cu, no visual quality indicator exists — mass spectrometry confirming the expected molecular weight is the only identity verification. The D-amino acid configuration means standard purity assessment by HPLC remains valid but the mass spec target (~4,826 Da) is essential for identity confirmation.
The D-retro-inverso synthesis is substantially more difficult and expensive than standard L-peptide synthesis. D-amino acids are more expensive raw materials. The reversed assembly requires additional quality control steps. The result: FOXO4-DRI has significantly higher per-milligram cost than most peptides in this book, and synthesis quality varies more between vendors. Substandard synthesis can produce truncated sequences that lack the correct binding geometry for FOXO4-p53 disruption — the compound then has no therapeutic effect (best case) or unpredictable off-target binding properties (worst case). For FOXO4-DRI specifically, mass spectrometry identity confirmation is not optional: it is the minimum acceptable quality assurance given the compound's p53-interacting mechanism and the higher stakes of getting the sequence wrong.
FOXO4-DRI's mechanism is the most molecularly precise of any compound in this book. It was designed from first principles to disrupt a specific protein-protein interaction in a specific cell type. Whether that specificity holds across human tissues, in aging humans with heterogeneous disease backgrounds, and at the doses achievable through subcutaneous injection, is what the missing human trials would answer.
Understanding FOXO4-DRI requires understanding what cellular senescence is and why it accumulates in aging tissue. Senescence is a cellular state triggered by irreparable stress: telomere erosion (from repeated cell division), unresolvable DNA double-strand breaks, oncogenic signaling (activated proto-oncogenes force a cell into protective senescence before it can become cancerous), oxidative damage, and other stressors. The senescent cell permanently exits the cell cycle — it will never divide again — but it survives, metabolically active, in tissues.
Senescence serves important short-term functions: it prevents potentially malignant cells from dividing; it recruits immune cells to sites of damage through SASP signals; it contributes to wound healing by promoting tissue remodeling. In young organisms with robust immune function, the immune system (particularly NK cells and macrophages) efficiently clears senescent cells before they accumulate. In aged organisms — or in any situation involving chronic senescence induction (chemotherapy, radiation, chronic disease) — clearance becomes inadequate and senescent cells accumulate. Their persistent SASP promotes chronic low-grade inflammation (inflammaging), degrades the extracellular matrix, impairs neighboring stem cells, and drives age-related tissue dysfunction.
Baar et al. identified that senescent cells specifically upregulate FOXO4 — a member of the Forkhead box transcription factor family — at levels 10-20x higher than proliferating cells. In the nucleus of senescent cells, this overexpressed FOXO4 physically binds to p53 and sequesters it in a conformation that prevents p53 from activating the mitochondrial apoptosis pathway. The senescent cell, in effect, holds its own death switch in the off position by capturing the trigger molecule. This FOXO4-p53 interaction is the survival mechanism of senescent cells — the reason they persist despite having sustained levels of DNA damage that would trigger apoptosis in younger, healthier cells.
When FOXO4-DRI is introduced, it competes with endogenous FOXO4 for p53 binding. The D-retro-inverso peptide mirrors the FOXO4 domain that contacts p53, outcompeting native FOXO4 for that binding site. Once FOXO4-DRI occupies the binding interface, p53 is released from sequestration and translocates out of the nucleus to the mitochondria. At the mitochondria, p53 activates BAX and other pro-apoptotic proteins, triggering the intrinsic apoptosis cascade — the cell death pathway. The senescent cell dies. Grade C: mechanism replicated in multiple independent cell types; mechanistic specificity confirmed; not yet validated at the pathway level in living human tissue.
The therapeutic claim rests on selectivity: FOXO4-DRI kills senescent cells but not healthy cells. The basis for this selectivity is the differential FOXO4 expression. In healthy proliferating cells, FOXO4 is expressed at basal levels. When FOXO4-DRI disrupts the FOXO4-p53 interaction in these cells, p53 is displaced — but in healthy cells, p53 is not sequestered by FOXO4 in the first place (it's free to perform its normal regulatory functions). Disrupting a binding interaction that isn't driving cell survival has minimal impact on cell fate in healthy cells.
The immunofluorescence and annexin V staining in the original Baar paper confirmed this: senescent fibroblasts (p16INK4a-positive, high FOXO4) underwent apoptosis after FOXO4-DRI treatment; proliferating fibroblasts did not. The selectivity ratio of 10-20x (senescent vs healthy cell sensitivity) provides the therapeutic window. This selectivity has been reproduced in chondrocytes (Frontiers in Bioengineering, 2021), endothelial cells (Frontiers in Bioengineering, 2025-2026), and keloid fibroblasts. Grade C: selectivity confirmed in multiple independent cell types in vitro; in vivo tissue selectivity in humans not established.
THE P53 PARADOX — THE CENTRAL SAFETY QUESTION
p53 is not only present in senescent cells. It is the primary tumor suppressor in every cell in the human body — present in proliferating cells, stressed cells, pre-cancerous cells, and cancer cells with altered p53 dynamics. FOXO4-DRI disrupts the FOXO4-p53 interaction. In senescent cells with 10-20x overexpressed FOXO4, this is the intended action. But p53 interacts with dozens of proteins and has context-specific functions throughout the body. In pre-cancerous cells that have begun accumulating p53 mutations, in cancer cells with inverted FOXO4-p53 dynamics, or in normal cells under acute stress where p53 behavior is transiently altered — the effect of FOXO4-DRI is not fully predictable. This is not documented harm from FOXO4-DRI. The mice were fine; the in vitro selectivity is real. But it is the most important theoretical safety question for any potential human therapeutic, and it is unresolved without human safety data.
Eliminating senescent cells removes the source of their SASP — the chronic inflammatory secretome that drives tissue dysfunction. In the aged mouse models, FOXO4-DRI treatment reduced circulating inflammatory cytokines, improved the tissue microenvironment, and appeared to partially restore stem cell niche function in cleared tissues. This SASP reduction is the mechanistic explanation for why systemic improvements (fur, kidney function, physical fitness) occurred from what appears to be a targeted cellular clearance intervention. Grade C: SASP suppression documented after FOXO4-DRI treatment in animal models; inflammatory marker changes are the expected downstream effect of senolysis.
FOXO4-DRI does not directly modify gene expression in the conventional sense — it disrupts a protein-protein interaction, releasing p53 to activate the intrinsic apoptotic cascade. The downstream transcriptional effects are primarily those of p53 acting on its apoptotic target genes (BAX, PUMA, NOXA) in senescent cells undergoing death. In surviving (healthy) cells, the transcriptional landscape is largely unchanged because the FOXO4-p53 interaction FOXO4-DRI targets was not the dominant survival mechanism in those cells. The 2025 Nature Communications structural study provided the first atomic-resolution characterization of the FOXO4-p53 interaction interface, confirming the disordered p53 transactivation domain as the key binding region and enabling rational improvement of FOXO4-DRI analogs with higher binding affinity and potentially greater selectivity.
The indirect transcriptional consequences of senescent cell clearance are more clinically relevant: reduction of SASP gene products (IL-6, IL-8, MMP-3, PAI-1) in the tissue microenvironment; restoration of stem cell niche gene expression programs in cleared tissues; reduction of NF-κB-driven inflammatory gene signatures. These downstream changes represent the mechanism by which local senolysis produces systemic functional benefits. The quantification of these changes in human tissues has not been published for FOXO4-DRI.
THE EVIDENCE GAP IN FULL — SHARPER THAN MOST
FOXO4-DRI has the most dramatic animal data of any compound in the longevity section of this book (24.8% lifespan extension, physical rejuvenation, organ function restoration). It also has zero human safety data, no registered clinical trial, and a mechanism involving p53 that introduces a theoretical safety concern that is not present for any other compound in this book. The contrast between the animal evidence quality and the human evidence absence is more extreme here than for MOTS-c. At least MOTS-c has human observational data (plasma levels, genetic associations). FOXO4-DRI has a spectacular mouse paper and community self-experimentation. That is the complete human evidence picture.
Application
Model
Evidence Level
Grade
Key Finding
Limitation
Physical rejuvenation (fitness, fur)
Aged + progeroid mice
Single animal study (Baar 2017)
C
Restored fitness, fur density, 24.8% median lifespan extension
One study; needs independent full replication
Renal function restoration
Aged mice
Single animal study (Baar 2017)
C
30% reduction in renal senescent cells; improved creatinine clearance
Animal model; not translated to human kidney disease
Chemotherapy aging reversal
Doxorubicin mouse model
Single animal study (Baar 2017)
C
Reversed chemo-induced weight loss, liver damage, physical decline
Animal; no human cancer survivor trial
Senescent human chondrocyte clearance
Human chondrocytes in vitro
Cell culture (Frontiers 2021)
C
Selective removal of p16+cells; proliferating cells spared
In vitro; not in living human joint
Endothelial senescence
Aged/progeroid mice + cell culture
2025-2026 independent studies
C
Improved vascular function; endothelial senescence reduced
Animal + cell culture; independent replication is positive signal
Human therapeutic benefit (any)
None
None
E/X
Community self-reports; no controlled data
No human trial of any kind
CRITICAL DOSING DISCLAIMER — MORE SERIOUS THAN MOST
There is no validated human dose for FOXO4-DRI. There is no Phase 1 study. There is no pharmacokinetic study. There is no allometric scaling validation. Community protocols are derived from the 2017 mouse study (5 mg/kg IP) scaled to humans by a conversion factor that has not been validated for this specific compound, route, or indication. Furthermore, FOXO4-DRI's mechanism involves disrupting p53-protein interactions — the most important tumor suppressor pathway in the human body. The appropriate caution here exceeds that for any other compound in this book. This section documents what the community does. It does not validate that any community protocol is appropriate, safe, or evidence-based for humans.
Adjust any input. The syringe draw updates live. Tap a preset row to load that dilution.
| BAC | Concentration | Per unit | Notes |
|---|---|---|---|
| 2 mL | 5,000 mcg/mL | 0.4 mcg | Standard |
| 5 mL | 2,000 mcg/mL | 1 mcg | Lower concentration for precise dosing at small amounts |
| 1 mL | 5,000 mcg/mL | 0.4 mcg | Smaller vial |
The D-retro-inverso design gives FOXO4-DRI exceptional proteolytic stability. Standard L-amino acid peptides are degraded by tissue proteases within minutes to hours. FOXO4-DRI resists this degradation — its biological half-life is substantially longer, likely hours to days, though no formal human pharmacokinetic study has been published. This extended tissue persistence is essential to the mechanism: the peptide must remain intact long enough to penetrate cells and disrupt the intracellular FOXO4-p53 interaction. Clearance is primarily renal for intact peptides of this size; the D-amino acid configuration may affect filtration dynamics. All of this is theoretical for humans.
The mouse study used intraperitoneal (IP) injection — direct delivery into the abdominal cavity with high bioavailability and rapid systemic distribution. Community protocols use SubQ injection, which has lower and more variable bioavailability and slower absorption than IP. Whether SubQ FOXO4-DRI reaches the intracellular concentrations needed to displace FOXO4 from p53 in senescent tissues — the fundamental pharmacological question — has not been measured in any species via the SubQ route.
Mouse dose: 5 mg/kg intraperitoneal, every other day for 3 weeks. To translate this to a human SubQ dose requires: (1) allometric scaling from mouse to human (standard factor ~12.3 for mg/kg, giving ~0.4 mg/kg human-equivalent); (2) route adjustment from IP (high bioavailability) to SubQ (variable, likely lower); (3) assumption that pharmacokinetics, protein expression levels, and receptor occupancy are comparable between species. None of these assumptions have been validated for FOXO4-DRI. The allometrically scaled human-equivalent dose for a 70 kg adult would be approximately 28 mg per injection via IP — substantially higher than community protocols. Community doses (1-5 mg SubQ) are far below this estimate. Whether these lower doses achieve meaningful FOXO4-p53 disruption in human senescent tissues, or whether they are simply producing no effect, is not known.
Protocol Type
Dose Per Injection
Frequency
Course Length
Rest Period
Conservative entry (community)
1-2 mg SubQ
Every other day
1 week (3-4 injections)
3-6 months
Standard community
2-5 mg SubQ
Every other day or daily
2-3 weeks
3-6 months
Higher community
5-10 mg SubQ
Every other day
2-3 weeks
6 months+
Mouse study protocol (reference)
5 mg/kg IP (~350 mg for 70kg human — IP)
Every other day
3 weeks
N/A (single course)
Important note: the highest community doses (10 mg SubQ) are still a small fraction of the allometrically scaled mouse-equivalent dose for a human via IP injection. Whether the SubQ route achieves adequate tissue distribution to produce meaningful senolysis is the fundamental unanswered question for any community protocol.
FOXO4-DRI: lyophilized powder reconstituted with bacteriostatic water. Solution is clear and colorless. Refrigerate at 2-8C after reconstitution; use within 30 days. Mass spectrometry confirming ~4,826 Da is the essential identity check — the complex D-retro-inverso synthesis makes sequence verification from mass spec important, as truncated sequences from synthesis errors could produce incorrect molecular weights. HPLC purity 99%+ minimum (the unusual amino acid configuration requires careful purity assessment).
Vial Size
BAC Water
Concentration
Volume for 2 mg
Notes
10 mg
2.0 mL
5,000 mcg/mL
0.4 mL (40 units)
Standard
10 mg
5.0 mL
2,000 mcg/mL
1.0 mL (100 units)
Lower concentration for precise dosing at small amounts
5 mg
1.0 mL
5,000 mcg/mL
0.4 mL (40 units)
Smaller vial
The community has developed a specific protocol around FOXO4-DRI that reflects the compound's apoptotic mechanism. Because FOXO4-DRI triggers programmed cell death, running it simultaneously with compounds that promote cellular survival, proliferation, or repair is considered counterproductive. Most community practitioners implement a 'clean window': pause all restorative, anabolic, or growth-promoting peptides (GH secretagogues, GHK-Cu, BPC-157, TB-500, IGF-1-promoting compounds) for at least 1 week before starting a FOXO4-DRI course and 1-2 weeks afterward. The rationale: let the senolytic clearance complete before stimulating tissue regeneration and repair in the cleared microenvironment. This sequencing — clear first, then rebuild — is mechanistically rational and consistent with how the mouse study was conducted (FOXO4-DRI was administered as a standalone intervention, not in combination with anabolic compounds).
In the Baar 2017 study and subsequent independent animal studies, FOXO4-DRI was well-tolerated. No significant toxicity was observed in naturally aged mice or accelerated aging models at the doses studied. Treated mice showed improved — not worsened — health parameters. The in vitro selectivity data (senescent cells die; proliferating cells survive) is consistent across multiple independent cell types. This is the complete published safety profile. There is no human safety data.
The following concerns are theoretical, mechanistically grounded, and currently uncharacterized in humans:
THE P53 SAFETY CONCERN — MUST BE UNDERSTOOD BEFORE USE
p53 is the most important tumor suppressor in the human body. It interacts with dozens of proteins in multiple cellular contexts. FOXO4-DRI is designed to disrupt FOXO4-p53 interactions specifically in senescent cells where FOXO4 is overexpressed 10-20x. The selectivity in vitro is real and replicated. But: (1) senescent cells are not uniformly defined or uniformly distributed — different tissues accumulate different types and proportions of senescent cells, and the FOXO4 overexpression ratio may vary; (2) pre-cancerous cells may have altered FOXO4-p53 dynamics that make them behave differently than the healthy proliferating cells used in selectivity controls; (3) p53 mutant cells (found in most human cancers and some pre-cancerous lesions) may respond to FOXO4 disruption in completely unpredictable ways. The mechanistic concern is not that FOXO4-DRI kills healthy cells in a Petri dish — it demonstrably does not at tested concentrations. The concern is what happens in the heterogeneous, genetically diverse cell populations of an aging human body with undetected pre-cancerous lesions, subclinical cellular damage, or p53 pathway alterations that a blood test would never reveal. This cannot be dismissed as theoretical speculation — it is the core pharmacological question that a Phase 1 trial would address. That trial has not happened.
Other theoretical concerns:
ABSOLUTE CONTRAINDICATION: ACTIVE MALIGNANCY OR RECENT CANCER HISTORY
This is the strongest contraindication in this book. FOXO4-DRI modulates p53 function. p53 is the primary tumor suppressor in every human cell. Anyone with active cancer, cancer within the past 5 years, known pre-cancerous lesions, or a strong hereditary cancer predisposition must not use FOXO4-DRI without comprehensive oncological evaluation and physician supervision. The theoretical risk of disrupting p53-protein interactions in cancer cells or pre-cancerous cells is not zero — it is unknown. Unknown risk in the context of a life-threatening disease is not an acceptable experimental condition for self-administration. This is not negotiable.
FOXO4-DRI is not FDA-approved for any indication. It is not on any compounding pharmacy approved list and has not been nominated for PCAC review. It exists exclusively as a research chemical in the US and most other jurisdictions. It is not a controlled substance. It is not currently listed on the WADA Prohibited List — unlike MOTS-c (S4 explicit) or BPC-157 (S0 banned) or TB-500 (S2 banned), FOXO4-DRI has not received enough regulatory attention to be specifically named in anti-doping frameworks. Athletes could technically use it without a WADA violation currently — but the absence of a WADA ban is a function of regulatory lag, not a safety signal. Cleara Biotech is the commercial entity developing Proxofim (their branded FOXO4-DRI) for kidney disease, COPD, and osteoarthritis — which implies the compound has reached the preclinical stage suitable for IND filing, but no Phase 1 data has been published.
FOXO4-DRI stacking is fundamentally different from any other compound in this book. Most peptides work by activating a beneficial biological process. FOXO4-DRI works by eliminating a specific cell population. The stacking logic is sequential rather than simultaneous.
The mechanistically coherent approach to combining FOXO4-DRI with other peptides is sequential, not concurrent. Phase 1: FOXO4-DRI senolytic course (2-3 weeks) to clear accumulated senescent cells and reduce SASP. Phase 2: rest period (1-2 weeks) to allow immune clearance of cellular debris and SASP resolution. Phase 3: regenerative/anabolic peptide protocols (BPC-157, TB-500, GHK-Cu, GH secretagogues) to rebuild tissue quality in the now-cleared microenvironment. The rationale: senescent cells impair stem cell function in adjacent tissue through their SASP. By clearing them first, the microenvironment becomes more permissive for the regenerative signaling that subsequent peptide protocols produce. This sequencing has mechanistic logic; it has no controlled comparison study.
Dasatinib + Quercetin (D+Q) is the most clinically studied senolytic combination, with human pilot data in IPF and chronic kidney disease patients. D+Q uses different mechanisms (BCL-2/BCL-XL inhibition via dasatinib; PI3K/AKT inhibition via quercetin) to clear senescent cells. Some practitioners in the longevity community rotate between D+Q and FOXO4-DRI on different cycles, reasoning that targeting different senescent cell survival mechanisms may clear different populations of senescent cells that any single approach misses. This is mechanistically coherent but entirely theoretical — no combination study exists. For individuals with a personal oncology history: D+Q has more human safety data; FOXO4-DRI's p53 mechanism makes it the riskier choice for the cancer-history population.
MOTS-c addresses the metabolic/mitochondrial dimension of aging (AMPK, glucose metabolism, mitochondrial biogenesis). FOXO4-DRI addresses the senescence/inflammatory burden dimension. These are genuinely non-redundant longevity mechanisms. The clear-then-rebuild logic applies: a FOXO4-DRI senolytic course followed by a MOTS-c metabolic optimization protocol addresses both senescent cell burden and mitochondrial function in sequence. No data supports this combination over either alone; the mechanistic argument is sound.
Injection site reactions: mild burning or sting at injection site (more common than with most peptides — attributed to local senolytic activity). Some users report fatigue or mild flu-like symptoms during the first course — potentially consistent with immune clearance of senescent debris and transient SASP burst.
The most commonly reported early benefit: reduced joint stiffness and improved joint comfort. Mechanistically consistent with reduced SASP-driven inflammation in joint tissues. Some users report skin quality improvements (less dullness, improved texture).
Gradual improvement in energy levels and recovery from exercise. Some users report cognitive clarity improvements — possibly consistent with reduced neuroinflammation as senescent glial cells are cleared. Hair density improvements in some users with age-related thinning.
Sustained improvement in functional markers that were noted earlier. The most committed users report bloodwork improvements: reduced inflammatory markers (CRP, IL-6), improved metabolic parameters.
Senescent cell burden documented to return toward baseline within 8-12 weeks post-treatment in animal models. This implies the benefits are not permanent — periodic courses (1-3 per year) may be needed to maintain reduced senescent burden.
Because no human clinical data exists, the following is derived from community self-reports. Grade E throughout. The community's experience of FOXO4-DRI is characteristically delayed and subtle compared to most peptides in this book — consistent with a mechanism that operates by eliminating cells rather than activating a direct signaling pathway.
Timeframe
Community-Reported Effects (Grade E — uncontrolled)
Days 1-7 (during course)
Injection site reactions: mild burning or sting at injection site (more common than with most peptides — attributed to local senolytic activity). Some users report fatigue or mild flu-like symptoms during the first course — potentially consistent with immune clearance of senescent debris and transient SASP burst.
Week 2-4 (post-course)
The most commonly reported early benefit: reduced joint stiffness and improved joint comfort. Mechanistically consistent with reduced SASP-driven inflammation in joint tissues. Some users report skin quality improvements (less dullness, improved texture).
Month 1-3
Gradual improvement in energy levels and recovery from exercise. Some users report cognitive clarity improvements — possibly consistent with reduced neuroinflammation as senescent glial cells are cleared. Hair density improvements in some users with age-related thinning.
Month 3-6
Sustained improvement in functional markers that were noted earlier. The most committed users report bloodwork improvements: reduced inflammatory markers (CRP, IL-6), improved metabolic parameters.
Post-course (key point)
Senescent cell burden documented to return toward baseline within 8-12 weeks post-treatment in animal models. This implies the benefits are not permanent — periodic courses (1-3 per year) may be needed to maintain reduced senescent burden.
THE PLACEBO PROBLEM IS ACUTE HERE
FOXO4-DRI's effects are purported to be subtle and delayed. The compound produces no acute drug-like experience. Community self-reports, without controls, cannot be distinguished from expectation effects, natural variation, lifestyle improvements coincident with starting a protocol, or actual biological effect. The animal study produced dramatic, measurable, objective improvements. The community human experience is self-reported subjective improvements in people who know what they took. These are categorically different evidence types. Both are reported here; they should be held differently.
The most important practical consideration for FOXO4-DRI is that its benefits are not permanent. Senescent cell burden returns to pre-treatment levels within 8-12 weeks post-treatment in animal models. This means the therapeutic approach requires periodic cycling — not a one-time intervention. The community typically runs 2-3 courses per year, each lasting 2-3 weeks, with extended breaks between. The rationale is to maintain reduced senescent burden rather than achieve permanent clearance. This cyclical approach also reduces cumulative exposure to the p53-interacting compound, which is a pragmatic risk mitigation given the absence of long-term human safety data.
FOXO4-DRI is among the most expensive peptides to produce correctly. The D-retro-inverso synthesis requires D-amino acids (2-5x more expensive than L-amino acids), specialized solid-phase peptide synthesis protocols, and careful quality control. Pricing 2026: reputable research vendor with HPLC + mass spec COA, 10 mg FOXO4-DRI: $150-300+. This is substantially higher per milligram than any other peptide in this book. This cost creates strong economic pressure toward cheaper synthesis — with higher risk of truncated sequences or impure product. A truncated FOXO4-DRI that lacks the correct binding geometry for FOXO4-p53 disruption is either inert (best case) or has unpredictable binding properties (concerning case). For this compound more than any other in this book, budget vendors should be avoided. The mass spec identity confirmation at ~4,826 Da is essential.
FOXO4-DRI has the most consequential open question list in this book, because the missing human data involves a compound that modulates p53 — a protein where off-target effects could theoretically cause cancer rather than prevent aging.
The honest position on FOXO4-DRI in 2026: the most biologically compelling case for a targeted longevity intervention in this book — a mechanistically elegant, selectively acting compound with one extraordinary mouse study — with a complete absence of human safety data and a mechanistic reason to be more cautious than for any other compound here. The p53 mechanism that makes FOXO4-DRI potentially transformative is the same mechanism that makes 'no human safety data' more alarming than for any compound in this book. Seven years after the landmark paper, no clinical trial has been initiated. That delay is itself a signal that the clinical development pathway has encountered challenges.
Research provenance: FOXO4-DRI has the most concentrated but genuinely multi-institutional evidence base in the longevity section of this book. The original Baar et al. 2017 paper is from Erasmus University, a premier aging research center — not a commercial developer. Independent replications have come from cartilage tissue engineering groups (Netherlands, 2021), Chinese universities (Wenzhou Medical University, 2025-2026 endothelial studies), and keloid research groups. The 2025 Nature Communications structural paper is from yet another independent group. The commercial development is by Cleara Biotech, a Netherlands startup. The evidence is geographically diverse and institutionally independent to a degree not seen in BPC-157 or the Russian neuropeptides.
Baar MP, Brandt RMC, Putavet DA, et al. (2017). Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 169(1):132-147.e16. PMID: 28340339. doi: 10.1016/j.cell.2017.02.031. [THE landmark paper: FOXO4-DRI designed; mechanism confirmed; fur restoration, renal recovery, 24.8% median lifespan extension in naturally aged mice; chemotherapy reversal model. Erasmus University Medical Center, Jan Hoeijmakers lab. This is the complete human-relevant evidence base.]
Pers YM, et al. (2021) [2]. Senolytic peptide FOXO4-DRI selectively removes senescent cells from in vitro expanded human chondrocytes. Frontiers in Bioengineering and Biotechnology. PMC8116695. [Independent group; human cell culture — most directly human-relevant data; selective chondrocyte senolysis confirmed; no proliferating cell toxicity]
Frontiers in Bioengineering and Biotechnology. (2025-2026). FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. doi: 10.3389/fbioe.2025.1729166. [Independent Chinese universities; vascular aging model; p53/BCL-2/Caspase-3 pathway confirmed; improved endothelial and aortic function in aged mice]
Zhang et al. (2020). FOXO4-DRI decreased levels of p53, p21, and p16 in the testes of aged mice. [Testicular senescence application; independent replication of senolytic mechanism in reproductive tissue]
Nature Communications. (July 2025). The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. doi: 10.1038/s41467-025-60844-9. [Atomic-resolution structural characterization of the FOXO4-p53 interaction; confirms binding geometry FOXO4-DRI was designed to disrupt; independent group; enables rational analog improvement]
A FOXO4 Inhibitory Peptide Limits Chemotoxicity in Mice. Cancer Discovery. 7(6):OF21. 2017. doi: 10.1158/2159-8290.CD-RW2017-064. [Summary of the Baar paper in cancer context; FOXO4-DRI reversal of doxorubicin-induced senescence/chemotoxicity; AACR publication]
PMC8601985. Development of a novel senolytic by precise disruption of FOXO4-p53 complex. [Review article discussing FOXO4 blocking peptides, selectivity requirements, and the need for deeper understanding of senolytic mechanisms and toxicity before clinical use]
Nature Communications Biology. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. [Independent application in keloid scarring — another tissue type confirming the mechanism]
FOXO4-DRI is the compound that makes the strongest biological argument for a transformative longevity intervention in this book — and the compound that makes the strongest argument for waiting for human safety data before self-experimenting. These are not contradictory positions. They reflect the actual state of evidence.
The central tension resolved: the 2017 Baar et al. Cell paper is genuinely extraordinary. A compound that selectively eliminates senescent cells by releasing p53 from sequestration, restoring fur, renal function, and physical fitness in aged mice, and extending median lifespan by 24.8% — this is not marginal biology. If the mechanism translates to humans at accessible doses, FOXO4-DRI or its analogs could represent one of the most significant longevity therapeutic advances in history. The compound works by interacting with p53 — the tumor suppressor that, when disrupted or mutated, enables most human cancers. Seven years after the landmark paper, no human safety trial has been initiated. Every longevity-focused biohacker who is injecting FOXO4-DRI is doing so without any human safety data for the class of compound they are using. That is a very different risk profile from other experimental compounds, where the risk is primarily 'we don't know if it works.' Here, the risk is 'we don't know if it's safe, and the mechanism is the same one that matters most for cancer prevention.'
The strongest argument for FOXO4-DRI: the selectivity mechanism is elegant and independently replicated in multiple cell types by multiple groups. The original paper is from a premier aging research institution, not a commercial developer. The independent replications (chondrocytes, endothelial cells, keloid fibroblasts) confirm the basic senolytic mechanism works in human cells — not just mouse tissue. Cleara Biotech's clinical development program (Proxofim) targeting kidney disease and COPD is a positive signal that someone with regulatory accountability has assessed this compound as worthy of clinical development. Senescent cell clearance is one of the most mechanistically compelling anti-aging strategies in academic geroscience.
The strongest argument for caution: p53. Every argument for caution flows from the p53 mechanism. The compound modulates p53 availability in cells. p53 dysfunction is found in ~50% of all human cancers. The community using this compound self-administers it without any characterization of their p53 pathway status, without any tumor burden assessment, and without any physician oversight of the theoretical cancer risk. The absence of reported adverse events in community use is consistent with the compound being safe — but community self-reporting is not a safety monitoring system. Undetected adverse events (a slowly progressing cancer in a p53-compromised context, for example) would not show up in community forums for years.
FOXO4-DRI is the compound that makes the strongest biological argument for a transformative longevity intervention in this book — and the compound that makes the strongest argument for waiting for human safety data before self-experimenting. These are not contradictory positions. They reflect the actual state of evidence.
The central tension resolved: the 2017 Baar et al. Cell paper is genuinely extraordinary. A compound that selectively eliminates senescent cells by releasing p53 from sequestration, restoring fur, renal function, and physical fitness in aged mice, and extending median lifespan by 24.8% — this is not marginal biology. If the mechanism translates to humans at accessible doses, FOXO4-DRI or its analogs could represent one of the most significant longevity therapeutic advances in history. The compound works by interacting with p53 — the tumor suppressor that, when disrupted or mutated, enables most human cancers. Seven years after the landmark paper, no human safety trial has been initiated. Every longevity-focused biohacker who is injecting FOXO4-DRI is doing so without any human safety data for the class of compound they are using. That is a very different risk profile from other experimental compounds, where the risk is primarily 'we don't know if it works.' Here, the risk is 'we don't know if it's safe, and the mechanism is the same one that matters most for cancer prevention.'
The strongest argument for FOXO4-DRI: the selectivity mechanism is elegant and independently replicated in multiple cell types by multiple groups. The original paper is from a premier aging research institution, not a commercial developer. The independent replications (chondrocytes, endothelial cells, keloid fibroblasts) confirm the basic senolytic mechanism works in human cells — not just mouse tissue. Cleara Biotech's clinical development program (Proxofim) targeting kidney disease and COPD is a positive signal that someone with regulatory accountability has assessed this compound as worthy of clinical development. Senescent cell clearance is one of the most mechanistically compelling anti-aging strategies in academic geroscience.
The strongest argument for caution: p53. Every argument for caution flows from the p53 mechanism. The compound modulates p53 availability in cells. p53 dysfunction is found in ~50% of all human cancers. The community using this compound self-administers it without any characterization of their p53 pathway status, without any tumor burden assessment, and without any physician oversight of the theoretical cancer risk. The absence of reported adverse events in community use is consistent with the compound being safe — but community self-reporting is not a safety monitoring system. Undetected adverse events (a slowly progressing cancer in a p53-compromised context, for example) would not show up in community forums for years.
Senolytic Approach
Mechanism
Human Data
Cancer Risk Mechanism
Notes
Dasatinib + Quercetin
BCL-2/BCL-XL inhibition + PI3K/AKT
Phase 2 human pilot data (IPF, CKD)
Dasatinib inhibits BCL-2 (cancer-relevant but approved drug)
Most clinically validated; physician-supervised access
FOXO4-DRI
FOXO4-p53 disruption → apoptosis
Zero — mouse and cell only
Direct p53 interaction — most concerning mechanism
Most dramatic animal data; most theoretical human risk
Navitoclax (ABT-263)
BCL-2/BCL-XL inhibitor
Phase 1/2 human data in cancers
Cancer-class drug; significant thrombocytopenia
Potent senolytic; too toxic for non-cancer use currently
Fisetin (high-dose)
Multiple anti-apoptotic pathways
Phase 1 pilot in elderly
Flavonoid — low systemic risk
Weakest mechanism; most accessible; human safety reasonable
If FOXO4-DRI has an appropriate use case for self-experimentation, it is narrowly defined: adults over 50 with no personal or strong family cancer history, no known pre-cancerous lesions, with physician awareness (if not oversight) of the experimental protocol, who understand that they are using a compound with extraordinary mouse data and no human safety profile, and who implement the full contraindication checklist before proceeding. This is a narrow profile. Anyone outside it faces risk that this chapter cannot characterize.
Not appropriate for: anyone with active cancer (absolute contraindication — p53 mechanism); anyone with cancer history in the past 5 years (hard stop without oncologist consultation); anyone with known genetic cancer predisposition (BRCA, Lynch syndrome, Li-Fraumeni) without thorough oncologist discussion; anyone who cannot or will not implement the clean window protocol; anyone expecting acute drug-like effects — FOXO4-DRI produces delayed, subtle changes consistent with cellular clearance, not pharmacological activation.
Senolytic Approach
Mechanism
Human Data
Cancer Risk Mechanism
Notes
Dasatinib + Quercetin
BCL-2/BCL-XL inhibition + PI3K/AKT
Phase 2 human pilot data (IPF, CKD)
Dasatinib inhibits BCL-2 (cancer-relevant but approved drug)
Most clinically validated; physician-supervised access
FOXO4-DRI
FOXO4-p53 disruption → apoptosis
Zero — mouse and cell only
Direct p53 interaction — most concerning mechanism
Most dramatic animal data; most theoretical human risk
Navitoclax (ABT-263)
BCL-2/BCL-XL inhibitor
Phase 1/2 human data in cancers
Cancer-class drug; significant thrombocytopenia
Potent senolytic; too toxic for non-cancer use currently
Fisetin (high-dose)
Multiple anti-apoptotic pathways
Phase 1 pilot in elderly
Flavonoid — low systemic risk
Weakest mechanism; most accessible; human safety reasonable
— End of FOXO4-DRI —
THE PEPTIDE BIBLE | FOXO4-DRI | For Research & Educational Purposes Only
FOXO4-DRI (also known as Proxofim) is a synthetic D-retro-inverso senolytic peptide, molecular weight ~4,826 Da. D-retro-inverso = all D-amino acids in reversed sequence, conferring near-complete proteolytic resistance and extended biological half-life versus standard L-peptides. Developed at Erasmus University Medical Center by Marjolein Baar et al. Primary mechanism: FOXO4 is overexpressed 10-20x in senescent cells vs healthy cells; it sequesters p53 in the nucleus, preventing apoptosis and allowing senescent cells to persist. FOXO4-DRI competes for the FOXO4-p53 binding site, releasing p53 to trigger mitochondrial apoptosis specifically in cells with high FOXO4 overexpression (senescent cells). Selectivity confirmed in vitro in human fibroblasts, chondrocytes, endothelial cells, and keloid fibroblasts — multiple independent groups. Landmark evidence: Baar et al. 2017 (Cell, PMID: 28340339) — 5 mg/kg IP every other day x 3 weeks in aged mice: restored fur density, improved renal function, improved physical fitness, 24.8% median lifespan extension. Senescent cell burden returns to baseline 8-12 weeks post-treatment — implying periodic cycling is required. 2025 Nature Communications: atomic-resolution structure of FOXO4-p53 interface confirmed. 2021 Frontiers study: selective clearance of senescent human chondrocytes in vitro. 2025-2026 Frontiers: independent confirmation in vascular endothelial senescence. Human clinical evidence: ZERO — no Phase 1, no clinical trial, no registered study. Community protocol: 1-5 mg SubQ every other day, 2-3 week courses, 1-3 times per year. All empirical — allometric scaling from mouse dose suggests community doses may be substantially below effective dose. ABSOLUTE CONTRAINDICATION: active malignancy or recent cancer history — FOXO4-DRI modulates p53 function; p53 is the primary tumor suppressor; off-target effects in p53-compromised cells are theoretically catastrophic and not characterized. Clean window protocol: pause all anabolic/restorative peptides 1-2 weeks before and after courses. FDA: not approved; research chemical only; not PCAC-reviewed. WADA: not currently listed. Commercial development: Cleara Biotech pursuing Proxofim for kidney disease, COPD, osteoarthritis — no Phase 1 data published. The central tension: the most compelling longevity biology in this book paired with the most mechanistically serious safety concern in this book. The p53 mechanism that makes FOXO4-DRI potentially transformative is the same mechanism that makes 'no human safety data' more alarming here than for any other compound in the project.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.